SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Clinical trials for SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK explained in plain language.
Never miss a new study
Get alerted when new SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK trials appear
Sign up with your email to follow new studies for SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New cancer drug trial halted early after testing in just 10 patients
Disease control TerminatedThis early-phase study tested a new drug (PF-07826390) alone or with another drug (sasanlimab) in 10 people with advanced solid tumors like lung, colon, or kidney cancer. The goal was to check safety and find the right dose. The study was terminated early, so results are limited.
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated May 26, 2026 11:52 UTC
-
New cancer drug trial halted early: what we know
Disease control TerminatedThis study tested a drug called PF-08046052/SGN-EGFRd2 in people with advanced solid tumors that could not be removed or had spread. The goal was to find a safe dose and check for side effects. The trial was terminated early, so results are limited. It involved 68 participants wi…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated May 26, 2026 11:48 UTC
-
Head and neck cancer drug trial halted midway
Disease control TerminatedThis study tested whether adding the drug Xevinapant (Debio 1143) to standard chemotherapy and radiation could help people with advanced head and neck cancer live longer without the cancer growing. The trial planned to enroll 730 adults with previously untreated, locally advanced…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: PHASE3 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated May 26, 2026 11:36 UTC
-
Can your own tumor cells beat cancer? new trial puts immune cells to the test
Disease control TerminatedThis study tested a treatment that takes immune cells from a patient's own tumor, grows them in a lab, and gives them back to fight cancer. It included 225 adults with advanced melanoma, head and neck, or lung cancer. The goal was to see if these cells could shrink tumors and how…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: PHASE2 • Sponsor: Iovance Biotherapeutics, Inc. • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
Pfizer's new cancer drug shows early promise in small trial
Disease control TerminatedThis early-stage study tested a new drug, PF-07820435, alone or with another drug (sasanlimab), in 9 people with advanced solid tumors like lung, skin, and kidney cancers. The main goal was to check safety and find the right dose. The study was stopped early, so results are limit…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
Experimental combo for advanced head and neck cancer shows early safety signals
Disease control TerminatedThis early-phase study tested whether adding the immunotherapy drug pembrolizumab to standard chemoradiotherapy is safe for people with stage IV head and neck cancer. Only 3 participants were enrolled before the study was stopped. The main goal was to find the highest safe dose a…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: PHASE1 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated May 20, 2026 11:54 UTC